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THE COMPARATIVE ROLE OF DEMINERALIZED BONE MATRIX 
PLACEMENT ON THE PERIOSTEUM VERSUS IN THE MUSCLE WITH AND 
WITHOUT BONE MORPHOGENETIC PROTEIN 2 
ALEXANDRA L. FEMIA 
ABSTRACT 
Demineralized bone matrix (DBM) is an allograft material used in orthopaedics that 
promotes endochondral bone formation.  While the placement of DBM on either the 
periosteal surface of a bone or within a skeletal muscle promotes the recruitment of stem 
cells that can form skeletal tissues through the temporal progression of endochondral 
bone development, it remains unclear to what degree these processes are different 
between the two sites.  In this study, we utilize a comparative in vivo model of 
endochondral ossification by implanting the DBM on the periosteum and in the muscle.  
Within the muscle we further compared the effects of DBM with and without Bone 
morphogenetic protein-2 (BMP-2), a primary morphogenetic factor involved in the 
differentiation of skeletal stem cells.  The mice were harvested at various time points 
after DBM implantation in order to analyze the development of the bone. Analysis 
included X-ray imaging, microCT imaging, and mRNA expression.  Plain x-ray and 
micro-CT imaging analysis showed mineralized bone formation in the implant on the 
periosteum and in the muscle with BMP-2, but no growth in the muscle when BMP-2 
was not added to the DBM. The mechanisms for bone development were further analyzed 
by qRT-PCR to determine temporal patterns and levels of expression of various stem cell 
and differentiated skeletal cell associated genes.  The stem cell gene expression varied 
	  	   vii 
between implant placement locations suggesting different mechanisms for stem cell 
recruitment.  Interesting, while DBM implants in the muscle without BMP did not induce 
mineralized tissue specific mRNA expression; specific stem cell and early skeletal cell 
lineage commitment genes were present.  These results suggest that while DBM in 
muscle is capable of recruiting stem cells that higher BMP-2 levels are needed to promote 
the progression of cartilage to mineralized bone in muscle tissues.  
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INTRODUCTION 
 
 Orthopaedics focuses on bone development and repair as an attempt to alleviate 
the high percentage of bone related injuries and ailments affecting U.S. citizens. In the 
United States, 6 million people break or fracture a bone each year (Physical Fields 1). In 
addition, 4.5 million women and 1 million men over the age of 50 suffer from 
osteoporosis (Amin 1). A better understanding of the processes underlying bone 
formation, remodeling, and repair is vital due to the large population that is affected by 
bone related conditions.  
 Bone development is a highly regulated process. Endochondral ossification, the 
method by which the appendicular skeleton is formed, utilizes a cartilage model prior to 
ossification. This development of cartilage and bone is facilitated through stem cells with 
skeletogenic potential and is orchestrated by a specific series of signaling processes that 
first recruit these stem cells and then lead them to proliferate and differentiate into their 
specific lineages (Provot et al. 658). While this overall process is well understood in 
embryonic development and primary bone formation, the mechanisms by which post-
natal skeletogenic stem cells are recruited and their tissue origins are undefined.  
 
Endochondral Ossification 
 The process of bone formation and growth can be carried out by one of two 
distinct processes: intramembranous ossification or endochondral ossification. 
Intramembranous ossification, primarily occurring in the skull and flat bones, occurs 
when mesenchymal cells directly differentiates into osteoblasts (Provot, et al., 658). The 
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remainder and majority of the skeleton develop via endochondral ossification. This 
process involves the formation of a cartilage template, which serves as a model onto 
which bone formation occurs with the cartilage intermediate phase being resorbed as 
osteoblast differentiation and bone formation progresses (Crombrugghe, et al. 721).  
 The development of the appendicular skeleton via endochondral ossification 
occurs in mesoderm cell layer -derived cells. This cell population appears early following 
the onset of the limb bud formation, and express sonic hedgehog gene (Shh), “which 
encodes a secreted protein involved in patterning and growth of the limb elements that is 
expressed in a localized region of the posterior limb mesenchyme” (Miclau, et al. 45).  
Shh is involved in the regulation of the expression of bone morphogenetic proteins 
(BMPs), fibroblast growth factors (FGFs), and with the induction of the Sox9 
transcription factor which directs mesenchymal cells towards their eventual chondrogenic 
lineage (Miclau, et al. 45). In addition to Shh, Hox genes also affect the expression of 
BMPs and FGFs, ensuring that the correct location of the limb elements during limb bud 
formation, and accounting for some of the mesenchymal cell proliferation (Hollinger 3).  
 As the undifferentiated mesenchymal cells begin to condense, condensation 
initiates cell signaling that specifically mediates its activity through Sox9 (Miclau et al. 
46).  Sox9 is a member of the Sox family of transcription factors and is essential for the 
differentiation of chondrocytes from osteo/chondroprogenitor cells (Crombrugghe, et al. 
721). It is expressed by proliferative chondrocytes, ensuring the expression of the 
cartilage matrix mRNAs, specifically type II collagen (Mackie et al. 55). Within the 
mesenchymal condensations besides Col2a1 the large proteoglycan aggrecan is also 
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normally expressed with both genes regulated by downstream enhancers of Sox9 
(Crombrugghe et al. 723). Following condensation the expression of two other Sox 
transcription factors (Sox5 and Sox6) increases in order to facilitate the progression of 
chondrocyte differentiation and proliferation (Crombrugghe et al. 723). As chondrocyte 
proliferation progresses the terminal differentiation of this lineage is defined by cellular 
hypertrophy extracellular matrix mineralization and apoptosis with the ossification 
occuring in distinct zones of the developing long bone.   
After the individual bones within limbs have been formed and at later stages of 
development, specific columnar arrangements of cells are retained farthest from the sites 
of midiaphyseal regions where initial ossification occurred. These sites contain resting 
chondrocytes that give rise to the growth plates within the individual bones of the limb. 
During subsequent longitudinal growth chondrocytes move from the resting into a 
proliferative state, where they divide and grow in column shaped clusters. As they 
continue to develop and divide they enter a state of hypertrophic growth. During this 
phase the chondrocytes increase significantly in size and secrete and mineralize their 
extracellular matrix.  The hypertrophic cells undergo apoptosis, leaving a scaffold of 
mineralized cartilaginous matrix. Blood vessels invade the region, bringing 
osteoprogenitor and hematopoietic cells to the site (Mackie et al. 55). The hematopoietic 
cells will become the site of the eventual bone marrow, while the osteoprogenitor cells 
differentiate into osteoblasts. The osteoblasts utilize the cartilage scaffold, secreting 
osteoid, forming bone onto of the original cartilage matrix (Kini and Nandeesh 36).  
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Stem Cell Expression 
 Stem cells have the ability to remain in an undifferentiated state while 
maintaining the capability to eventually differentiate. They are also defined by their 
capacity for self-renewal and to differentiate into one lineage (unipotent), multiple 
lineages (multipotent), or all three germ layers (pluripotent) (Punwar et al. 296). 
Mesenchymal stem cells have the ability to self-renew and differentiate into a variety of 
mesodermal tissues (Susanne et al. 4). In development, the earliest cells, totipotent cells, 
require specification to develop into over 200 different cell types. In a developing 
blastocyst, the embryonic stem cells affected are derived from the inner cell mass. In 
order to determine which lineage a cell will follow, transcription factors regulate gene 
expression in order to determine the cells fate. The exact process is still not completely 
understood (Boyer et al. 947).  
 Three central transcription factors identified in the differentiation of embryonic 
stem cells include Oct4, Sox2 and Nanog (Go et al. 1147). Oct4 is a member of the POU 
family of transcription factors, and recognizes the “consensus-binding motif 
ATGCAAAT” in the target DNA strand (Wei et al. 441). It has been linked to the 
differentiation of embryonic stem cells in the inner cell mass to trophoectoderm (Boyer et 
al. 947). Sox2 is member of the HMG box family and binds specifically to the “consensus 
sequence (A/T)(A/T)CAA(A/T)G” (Go et al. 1147). The levels of both Oct4 and Sox2 are 
decisive for embryonic stem cell fate. Increase in expression of Oct4 leads to the 
differentiation of stem cells into endoderm and mesoderm (Wei et al. 442). Nanog has 
been linked to the development and differentiation of cells in the extra-embryonic 
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endoderm (Boyer et al. 947). In previous studies, Nanog has appeared to interact via 
BMP signaling pathways by interfering with BMP’s induction of mesenchymal stem cell 
differentiation (Bais et al. 13). 
 In the determination of osteoprogenitor and chondrogenetic stem cell lineages, 
three stem cells factors were identified and considered for the purpose of our study: Prx1, 
Pax7, and Gremlin. Prx1 is a member of the paired- homeobox gene family that is 
predominantly expressed in the mesoderm that specifies limb buds. It has an important 
role in the interaction that occurs between the perichondrium and chondrocytes, 
specifically by regulating their proliferation and differentiation within the bone by 
enhancing the DNA binding specificity (Berge et al. 3831). Pax7 is expressed by satellite 
cells, which are “quiescent mononucleated myogenic cell able to proliferate in response 
to injury and give rise to regenerated muscle” (Morgan et al. 1151). The process by 
which the satellite cells proliferate is highly regulated through growth and transcription 
factors. When muscle is induced to proliferate, Pax7 binds to distinct regions of DNA to 
activate genes required for cell proliferation. As such, it plays a crucial role for the 
process of myogenesis (Maltzahn et al. 16474). Pax7 is instrumental in bone repair, 
specifically in fracture healing. When a fracture occurs, the stem cells in the surrounding 
skeletal muscle are activated during the inflammatory response period. These satellite 
cells help to regulate the inflammatory process in order for bone regeneration to occur 
(Abou-Khalil et al. 2).  Gremlin has recently been identified as an osteochondroreticular 
stem cell present in the bone marrow. These stem cells self-renew and differentiate into 
chondrocytes, osteoblasts, and reticular marrow stromal cells (Worthley et al. 269). It is 
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an antagonist for BMP-2, and is important for the development of bone  (Worthley et al. 
270). Identifying and understanding the earliest stem cell markers is important for 
understanding the origin of cells involved in osteogenesis and chondrogenesis.   
 
The Role of Bone Morphogenetic Protein-2 
  BMPs are a subfamily of the Transforming Growth Factor-β (TGF-β) 
superfamily. They have been identified as important factors in the growth and 
differentiation of mesenchymal cells into chondrocytic and osteoblastic lineages. This 
process occurs through a series of signal transduction steps that influence and regulate 
gene expression (Moucha, et al. 175).   BMPs are stored in the extracellular matrix of 
various bone tissue, osteoprogenitor cells, osteoblasts, chondrocytes and other bone 
related cells. During bone repair and remodeling the BMPs are released leading to the 
signal transduction and bone formation (Carreira et al. 338). The BMP focused on in this 
study is BMP-2 due to its role in skeletal repair and regeneration (Bragdon et al. 610). 
 BMP-2 signals through serine/threonine kinase receptors consisting of type I and 
type II receptors. The type I receptors include Alk3 and Alk6, and bind BMP ligands. The 
type II receptors have been identified as BMPR-II and type II/IIB activin receptors (Chen 
et al. 233). Once the ligand binds, type I receptors recruits the type II receptors which the 
type II receptors then phosphorylated the type I receptors initiating the BMP signaling 
cascade (Bragdon et al. 616). The type I receptor phosphorylates Smad1/5/8 proteins, 
which play a central role in the translocation of the BMP signal to the nucleus (Chen et 
al. 233). Once phosphorylated, Smad1 associates with related proteins (Smad 4) and 
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translocates into the nucleus where it regulates and affects gene transcription (Figure 1) 
(Chen et al. 234). 
Because BMP-2 has such a powerful role in the formation of bone, there are a 
number of molecular mechanisms that regulate it. Two important BMP-2 antagonists 
include Gremlin and Noggin (Bragdon et al. 613). Gemlin, a member of the Dan family 
of BMP antagonists is able to bind and block BMP-2. Gremlin primarily functions by 
modulating early limb growth through inhibiting chondrogenesis and apoptosis (Merino, 
et al. 5519). Noggin binds directly to BMPs, creating a complex, which can no longer 
bind to the cell surface receptors, and stopping the signal from beginning. BMPs 
stimulate Noggin secretion in mesenchymal cells, but may act as a negative feedback 
control in cell differentiation (Zhu et al. 2). In addition to antagonists, there are a number 
of mechanisms to block the transduction. Overall, there are many mechanisms to regulate 
the expression of BMP-2. This regulation is important because of the degree of 
importance BMP-2 plays in bone formation and growth.  
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Demineralized Bone Matrix 
 In orthopaedics, it is common to utilize bone grafts to supplement and enhance the 
healing process. There are a number of different graft options available including 
allografts, autografts, osteoinductive carriers and osteoinductive factors (Lee 218S). An 
osteoinductive graft has the ability to recruit stem cells and facilitates their differentiation 
while an osteoconductive graft has the ability to form a scaffold to which new bone can 
be formed (Lee 218S).An ideal bone graft has both osteoinductive and osteoconductive 
properties.  
 DBM is an “allograft bone void filler” and is processed directly from human 
tissue (DBM Demineralized Bone Matrix). It contains a number of important growth 
Figure 1: BMP-2 Signaling Pathway: The diagram illustrates the BMP-2 signaling 
pathway. The arrows denote positive regulators or enhancers while the lighter lines signify 
inhibitors of the process.  Figure taken from Chen et al..  
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factors, proteins, and collagenous material. The high presence of type I collagen allows 
for DBM to act as a scaffold for the new bone formation, fulfilling it classification as an 
osteoconductive graft material (Pietrzak 346). Furthermore, through the process of 
demineralizing the bone, BMPs become unmasked and available for use. The BMPs have 
an osteoinductive affect, recruiting and affecting the differentiation of the mesenchymal 
cells (Pietrzak 346). Other factors present collagen IV, X, growth factors, calcium 
phosphate, and cellular debris (Gruskin 1066). DBM facilitates in the formation of new 
bone, but it does not precisely follow the same procedure as endochondral ossification. 
DBM induces mesenchymal stem cells to differentiate into chondrocytes, which form 
cartilage. The cartilage is then ossified following the resorption of cartilage, as opposed 
to occurring simultaneously (Lee 219S). 
 DBM is continuing to grow as an alternative to previously used grafting material 
(Gruskin 1074). While this trend is accompanied by positive results, there are still a 
number of questions regarding the underlying processes that occur in the development of 
DBM into ossified bone. Because DBM is a human derived tissue, it is therefore variable 
between the different donors based on a number of different factors including age, sex, 
processing, and sterilization (Holt 1124). While the composition is generally similar, 
containing BMPs, collagen type 1, and other growth factors, the concentrations vary 
considerable between donors (Holt 1124). When BMP was analyzed across ten samples, 
concentrations ranged from 22-110pg for BMP-2 and 44 to 125pg for BMP-7, illustrating 
the huge variability of DBM between samples (Bae et al. 1). The variability has profound 
effects on the potency and osteoinductive capabilities of the DBM when used clinically. 
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In order to test for the potency of DBM, it is typically implanted in the muscle of an 
animal model and ectopic bone formation is measured (Lee 218S). Because clinically 
DBM is used on the periosteum directly but its potency is measured in the muscle, 
questions persist as to if it has differing effects on skeletogenic cells at these different 
tissue sites.  In addition, questions arise if there are in fact different populations of 
skeletogenic stem cells localized at these two different sites, if the quantities and 
temporal progression of bone formation will be different at the two tissue sites.    
Clinically, there are instances where bone allograft material is needed to 
supplement natural healing and bone strength (Grafton DBM Clinical Overview 3). In 
these instances, demineralized bone matrix (DBM) can be utilized as an osteoinductive 
material to induce bone formation (DBX® Demineralized Bone Matrix 1).  Although the 
processes by which DBM induces endochondral bone formation follows is similar to that 
of seen during development, the origins of the postnatal stem cell populations and exact 
processes of gene expression that contribute to these processes is far less understood. 
In this study DBM placed directly on the periosteal femur surface versus in a 
muscle pouch was used to the assess the magnitude of DBMs bone inductive properties at 
different tissue locations, the nature of the stem cells that are recruited at different tissue 
sites and the timing of specific genes expression indicative of endochondral bone 
developmental process.   A second focus of this study was the role that bone 
morphogenetic protein 2 (BMP-2), plays in skeletogenic stem cell differentiation that is 
mediated by DBM.   In this study we further compared DBM alone or combined with 
BMP-2 within the muscle pouch model.  Using this model, we determined how BMP-2 
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augmented the osteoinductive processes within the muscle by comparing the effects of 
the two different treatments endochondral bone formation associated on gene expression 
in the muscle.  
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SPECIFIC AIMS 
Aim 1. The objective of this study is to determine the effect of tissue site on DBM’s 
osteo-conductive and -inductive properties. 
 
Aim 2. These studies further focused on the variable effects that BMP-2 addition had on 
the osteo-conductive and -inductive properties of DBM.   
 
Methods:  Variable effects of tissue site on DBM’s properties were assessed by DBM 
implantation on periosteum of the femur or within a muscle pouch in the quadriceps 
femoris muscle.  In order to assess the effect of BMP-2 on DBM’s osteo-conductive and -
inductive properties exogenous BMP-2 was added to DBM that were implanted in the 
muscle and compared to DBM without BMP-2 addition.  The bone tissue formation was 
allowed to develop and was assessed from day 2-31 after surgery.  
• Plain X-ray and quantitative microCT- analysis was carried out to analyze the 
spatial development of the implant relative to the femur. Bone volume data was 
then generated to compare the growth of mineralized tissue from implants placed 
in the muscle to those placed directly on the femur.  
• RNA was extracted from the implant, and qRT-PCR preformed.  Analysis of 
genes specific to stem cell markers, osteogenesis, chondrogenesis, muscle 
development, angiogenesis, and BMP-2 signaling were compared.  
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• Statistical analysis was performed to determine significant difference in gene 
expressions between the DBM placed in the muscle and a previous analysis of the 
gene expression of DBM placed directly on the periosteum. 
Overall goal of these studies: determine if the site of placement effected the overall 
quantity and/or temporal progression of bone formation, assess if the origin or nature 
of the stem cells that contribute to the development of bone were different based on 
tissue site of implantation, and determine the role that BMP-2 plays in stem cell 
recruitment and or differentiation. 
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METHODS 
 
Animals & Surgery 
 All animal studies were approved by the Institutional Animal Care and Use 
Committee at Boston University. Mice were obtained from The Jackson Laboratory (Bar 
Harbor ME) and housed at the BU Animal facilities under standard conditions.  All mice 
were male between 9-11 weeks and of the strain B6-129S7Rag1tmMom/J. Mice were 
either unilaterally or bilaterally implanted with 0.0500 ± 0.0003 µg of Grafton® DBM 
Putty which was inserted into the muscle surrounding the femur. Prior to insertion in the 
muscle, the putty was combined with 0.3µg of BMP-2.  Preceding to, and following 
surgery mice were subcutaneously injected with a total of 0.1 mL of Buprenex® as pain 
medication and 0.01mL of Baytril® as antibiotics. Five mice were euthanized per time 
point at harvest days 2, 4, 8, 12, 16, 24, 31 post-surgery for RNA analysis. Mice 
harvested at days 8, 12, 24, and 31 received bilateral implants in order to perform 
MicroCT analysis as well.  
 
Harvest and X-Ray Imaging 
 Mice were euthanized at a given time point by carbon dioxide inhalation followed 
by cervical dislocation. Immediately following death, mice were X-rayed using Faxitron 
MX-20 Specimen Radiography System at 30 kV for 40 seconds using Kodak BioMax 
XAR Scientific Film. The implant, surrounding muscle, and femur were collected 
separately for RNA extraction and gene analysis. The samples isolated for RNA analysis 
were stored at -80 °C. On harvest days 8, 16, 24, and 31 the left limb was recovered for 
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MicroCT imaging. The limb was placed in 4% PFA for one week for fixation, and stored 
in1x PBS at 4°C.  
 
MicroCT Imaging 
 MicroCT imaging and analysis was performed on five mice at post-operative day 
8, 16, 24, and 31 using the SCANCO Medical µCT Scanner. The sample consisted of the 
limb with minimal muscle removed surrounding the implant and was scanned in a 20.5 
mm conical tube. Scans were taken at 70kVp and 114µA with an integration time of 
200ms. The imaging across time allowed for the temporal and spatial characterization of 
the DBM-induced mineralized tissue. Using SCANCO© Medical, the scans were 
manually contoured to include the implant in the muscle. The contour was analyzed using 
a total and bone volume script at a threshold of 240 based on a 45% evaluation of the 
cortical bone volume. The threshold was consistent with previous analysis and was set to 
detect the presence of mineralized bone. 
 
RNA Extractions 
 RNA extraction was performed by tissue dissociation and chemical extraction.  
Samples were snap frozen in 0.75mL of QIAzol® Lysis Reagent using liquid nitrogen. A 
5mm Qiagen® stainless steel bead was placed in each tube.  Samples were lysed with the 
Qiagen® Tissue Lyser II using 2-minute intervals at 30Hz; snap freezing the sample 
again if the sample thawed before being completely lysed. Samples were transferred to a 
new 2mL tube with the addition 1mL of QIAzol® Lysis Reagent and samples incubated 
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on ice for 2 minutes. After 2 minutes, 200µL of Chloroform (Sigma-Aldrich®) was 
added and the samples vortexed. Again, samples were incubated on ice for 2 minutes 
followed by vortexing, and centrifuged for 15 minutes at 14000rmp and 4°C. The 
aqueous phase was transferred to a new 2mL tube, adding an equal volume of 
isopropanol (Sigma-Aldrich®). This new solution was then centrifuged for 30min at 4°C 
and 14000rpm. 
 The supernatant was removed and the pellet washed with 500µL of 70% ethanol 
(Sigma-Aldrich®), and centrifuged for 5 minutes at 4°C and 14000rpm. The supernatant 
was removed and the pellet was washed again.  The ethanol was removed and the pellets 
were left to dry for 20-30 minutes. Once dry, pellets were re-suspended in 30-50 µL of 
RNAse free water by slowly pipetting up and down. The extracted RNA was the stored at 
-80°C. 
 In order to ensure the quality and quantity of the extracted RNA, both 
spectroscopy and gel electrophoresis were used. For the spectroscopy, 1µL of RNA was 
dissolved in 99 µL of RNAse free water. Using a Beckman Coulter™ DU®530 Life 
Science UV/Vis Spectrophometer, a 260nm/280nm ratio value in the range of 1.3-1.8 
indicated an acceptable quality of RNA. The 260nm absorbance value was used to 
determine the concentration of RNA in the sample. For the gel, 1µL of RNA, 7µL of 
RNAse free water, and 2µL of 6X Agarose Gel Loading Dye were mixed and loaded into 
1% agarose gel. The gel was made with UltraPure™ agarose from Invitrogen and 
GelStar™ Nucleic Acid Gel Stain from Lonza Group to detect the presence of the nucleic 
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acid in the gel. The gel was run at 110V for 60-90 minutes. The presence of two bands 
under UV light indicates the RNA is intact and a relative idea of the concentration.  
 
cDNA Production 
 RNAse free-water was added to 1µg of the extracted RNA in a 0.2mL PCR tube 
for a total volume of 10.4 µL. The following reagents were mixed in an eppendorf tube to 
create a mixture with a total volume of 19.6µL: 6.61µL of MgCl2, 6.0µL of dNTP Mix, 
3.0µL of 10X RT Buffer, 1.5µL of Random Hexamers, 0.6µL of RNAse Inhibitor, and 
1.89µL of Taqman Reverse Transcriptase. All of the reagents were obtained from the 
TaqMan® Reverse Transcription Reagents kit from Applied Biosystems®. The master 
mix was then added to the 0.2mL PCR tube to bring the final volume to 30 µL. The 
samples were placed in the Eppendorf Mastercycler® Personal thermal cycler. The PCR 
cycle ran at the following settings: 25°C for 10 minutes, 37°C for 60 minutes, 95°C for 5 
minutes, and finally, a 4°C hold. Following the PCR cycle, RNAse free water was used to 
make a 1:25 dilution of the cDNA, and the final samples were stored at -20°C. 
 
qRT-PCR  
 For qRT-PCR, a 96-well qPCR plate was used, running doublets of each sample 
on a single plate. We combined 10 µL TaqMan® Universal PCR Master Mix from 
Applied Biosystems® and 1 µL TaqMan® Gene Expression Assays primer from Applied 
Biosystems® for a total of 11µL of per sample. The primers used in this study can be 
observed in Table 1. In addition to our DBM samples, non-operative femurs were used as 
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our controls. The 11µL of mix was combined with 9µL of cDNA to bring the total 
volume to 20µL per well. After the plate was filled, it was then centrifuged, covered with 
clear film and analyzed using ABI 7700 Sequence Detector® from Applied 
Biosystems®. The qRT-PCR reaction repeated the following cycle 40 times: 50°C for 2 
minutes, 95°C for 10 minutes, 95°C for 15 seconds, and 60°C for 1 minute. The threshold 
cycle (Ct) values were obtained giving a measure of the concentration of the target gene. 
The Ct value for the target gene was normalized by two different methods. The first 
method normalized the target gene Ct value to the 18s Ct value and then compared the 
fold expression to control femur. The second method normalized the target gene Ct value 
to 18s. In addition, the gene expression was determined for native muscle in order to 
visualize and quantify the fold increase from baseline.  
 
Statistical Analysis  
 The statistical analysis of the data was accomplished using Microsoft® Excel® 
2011and JMP® 11.2.0. In order to calculate statistical significance, we used a multiple 
comparison t-test and Wilcox test with significance being p<0.05.  
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Table 1: qRT-PCR Primers. Primers used with their catalog numbers.  
Primer Catalog Number 
Normalization Primer  
18s Mm03928990_g1 
Stem Cell Primers  
Sox2 Mm03053810_s1 
Prx1 Mm00440932_ml 
Pax7 Mm01354484_m1 
Nanog Mm02384862_g1 
Oct4 (Pou5fl) Mm03053917_g1 
Gremlin Mm00488615_s1 
Cartilage Primers  
Sox9 Mm00448840_m1 
Sox5 Mm01264584_m1 
Col10a1 Mm00487041_m1 
Acan Mm00545794_m1 
Col2a1 Mm00491889_m1 
BMP Associated Primers  
Noggin Mm00476456_s1 
BMP2 Mm01340178_m1 
BMPR1a (Alk3) Mm00477650_m1 
BMPR1b (Alk6) Mm00432117_m1 
BMPRII Mm00432134_m1 
Bone- Associated Primers  
Osteocalcin (bglap) Mm03413826_mH 
ID1 Mm00775963_g1 
RUNX2 Mm00501578_m1 
DMP1 Mm00803833_g1 
Osterix (Sp7) Mm04209856_s1 
Muscle-Associated Primers  
MSTN Mm01254559_m1 
α-Sma (Acata2) Mm00725412_s1 
Angiogenesis Primer  
VE-Cadherin (CDH5) Mm03053719_s1 
SMA (Acta2) Mm00725412_s1 
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RESULTS 
X-ray Imaging  
 
 In a pilot study, DBM was combined with various concentrations of BMP-2 prior 
to being placed in the muscle. The concentration of BMP-2 was varied in order to 
determine the lowest concentration that induced bone formation. The concentrations 
tested were:  0.0µg, 0.1 µg, 0.3µg, 0.5µg, and 1.0µg.  From the x-ray imaged (Figure 2), 
a concentration of 0.3µg was determined and used for the experiment.  
Plain film X-rays were obtained at the time of harvest to visualize the mineralized tissue 
that formed due to the DBM implant. In Figure 3, the X-ray images of the DBM implant 
when placed on the periosteum is compared to the DBM placed within the muscle with 
and without BMP-2.  The X-ray images showed mineralized tissue at the implant site 
Figure 2: Effects of Varying Concentrations BMP-2 on DBM’s Osteo -Conductive and -Inductive Effect. 
Bone. Growth in the Muscle with varying doses of BMP-2. The concentrations of BMP-2 are denoted in the 
figure. Arrow indicates mineralized tissue induced by the DBM and BMP-2. 
	  21 
when placed on the periosteum and in the muscle with BMP-2 as early as day 12 and 
continuing through day 31.  The implant placed in the muscle without BMP-2 displayed 
no visible growth.  
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Figure 3: Effects of Tissue Placement and BMP-2 on DBM’s Osteoinductive and 
Osteoconductive Effect. Bone growth at each time point, DBM placed on the periosteum, 
in the muscle without BMP-2 and in the muscle with BMP-2. The yellow arrow indicates 
the presence of bone growth. The experimental group and time points are denoted in the 
figure. 
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MicroCT40 Imaging and Analysis  
  
 The total volume (TV) and the bone volume (BV) of each implant were quantified 
using the MicroCT40 and this data was compared to previous analysis of the DBM 
implant placed directly on the femur as well as in the muscle without BMP-2.  When 
analyzing the samples, a threshold of 240 was determined in order to measure how the 
placement of the implant affected its mineralization. This threshold was determined by 
using 45% of the mean bone volume of the cortical bone. The analysis was performed at 
a lower threshold (35% of the mean bone volume) in order to determine if the inclusion 
of more material would lead to greater significance, but no difference was found between 
the two thresholds.   As a result, a 240 threshold was used across all samples.  For both 
previous experiments, MicroCT40 scans were taken and analyzed.  The DBM implant on 
the periosteum induced detectable bone formation, but the implant in the muscle without 
BMP-2 displayed no detectable growth. The TV and BV comparison illustrates the 
comparison between the implant placed on the periosteum and in the muscle with BMP-
2. The TV comparison, Figure 4, shows significantly increased total size of the implant in 
the muscle with BMP-2. This increased size remained consistent throughout days 16, 24, 
and 31. The BV comparison, Figure 3, shows increased mineralization of the DBM 
placed on the periosteum at days 12 through 31 compared to the DBM/BMP2 implant. 
Throughout the time points the DBM placed in the muscle with BMP-2 continues to 
increase in BV, but never remains significantly smaller. Using JMP software, an 
ANOVA was conducted to determine statistical significance of the DBM implant when 
placed on the periosteum versus in the muscle with BMP-2 through the time course.  
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The 3D renderings, Figure 5, of the femur and implant illustrated the spatial 
positioning of the implant relative to the femur, ensuring that no contact was made 
between the two. This is important to accurately determine the effect of the placement on 
the implant’s growth and development. The images allow for the TV and BV to be 
related to the implant’s size and visual density.  
	  Figure 4: Effect of Tissue Placement and BMP-2 Addition on DBM’s Total and Bone Volumes. The top graph illustrates the comparative total 
volume between the three experimental groups. The bottom graph illustrates 
the comparative bone volume between three experimental groups. No visible 
growth is indicated with ND. The x-axis is the day post- harvest. The * 
indicates significance (p<0.05), error bars show SEM, n=5.  
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Figure 5: 3D Renderings of the Effect of Tissue Placement and BMP-2 Addition 
on DBM Growth. 3D renderings of the implant (orange) relative to the femur (gray) 
are displayed for days 16, 24, and 31 post-harvest. The line through the femur 
represents where the cut plane was taken. The smaller box is the cut plane (purple) 
looking through the femur.  
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q-RT-PCR Results 
 Although the DBM placed in the muscle with BMP-2 was able to induce the 
formation of bone shown by the BV, the development of this bone significantly lagged 
behind that of the DBM placed on the periosteal surface.   In order to elucidate a possible 
mechanism between the implants and the relative gene expression for stem cell 
recruitment, endochondral ossification, and selected BMP signaling molecules were 
analyzed. Following analysis, the fold gene expression was illustrated in two ways: 
normalized to control femur and normalized to 18s. This method was applied in order to 
gain insight into the overall levels of gene expression relative to cell number in the 
volume of tissue that was analyzed.  The expression of the genes in native muscle was 
also determined in order to compare relative increases in each experimental group. The 
two normalizations illustrated similar results in many cases, but there were some 
differences observed.  
 
Stem Cell Recruitment 
 A number of early stem cell markers including: Sox2, Nanog, Oct4, Gremlin, 
Prx1, and Pax7 were analyzed in order to determine the earliest factors driving bone 
formation. In our analysis we not only looked at the DBM-induced expression in the 
muscle with BMP-2, but also compared it to previous studies where DBM was placed 
directly on the periosteum and in the muscle with no BMP-2.   
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 Sox2, Nanog, and Oct4 showed very similar trends in the DBM implant placed on 
the periosteal surface. The DBM placed on the periosteum displayed increased expression 
at day 2 and day 4 followed by a decrease at days 8 through 31.  
 Sox2, when normalized to control femur, was significant at day 4 between the 
implant placed on the periosteum and the implant in the muscle both with and without 
BMP-2 (p=0.0304). When normalized to 18s, there was significance at day2 between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 
(p=0.0304).  
 Nanog, when normalized to control femur, displayed both a significant difference 
in expression between the implant placed on the periosteum versus the implant in the 
muscle with BMP-2 as well as the implant place in the muscle with BMP-2 versus 
without BMP-2 at days 4, 12, 16, 14, 31 (p<0.002). At day 8 there was significant 
difference between all three experimental groups (p<0.001). When normalized to 18s, 
there were significant differences at days 8, 16, and 31 between the implant placed on the 
periosteum versus both the implants in the muscle with and without BMP-2 (p<0.003). In 
addition the peak at day 2 in the implant on the periosteum was significant from the 
implant placed in the muscle with BMP-2 (p=0.0304).  
 Oct4 expression showed similar trends of significance between the two 
normalizations. At days 4, 8, 12, 16, 24, and 31 there was significant differences in 
expression between the implant in the muscle with and without BMP-2 (p<0.03). When 
normalized to control femur there was also significant differences in expression at days 4, 
8, 12, and 16 between the implant placed on the periosteum versus the implant placed in 
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the muscle without BMP-2 (p<0.03). When normalized to 18s, there was significant 
differences in expression at day 8 between the implant placed on the periosteum versus 
the implant placed in the muscle without BMP-2 (p=0.0058) and at day 31 between the 
implant placed on the periosteum versus the implant placed in the muscle BMP-2 
(p=0.0367), 
 Germlin’s expression varied most dramatically between the two different methods 
used for the normalization of gene levels.  When normalized to control femur, there is 
increased expression in the implant placed in the muscle without BMP-2 with a peak at 
day 8. Statistically, there is significant differences in expression at days 8, 12, 16, 24 
between all three experimental groups (p<0.03) and at day 31 between the implant placed 
on the periosteum and both implants in the muscle (with and without BMP-2) with 
p=0.0200. When normalized to 18s, the implant in the muscle with BMP-2 displays 
increased fold expression throughout all time points. There are significant differences in 
expression at days 8 and 12 between all three experimental groups, and at days 12, 16, 
24, and 31 between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 (p<0.02), as well as between the implant placed in the muscle with 
and without BMP-2 (p<0.03). 
 Pax7 appears to have increased expression in the DBM implant on the periosteum 
compared to the implant placed in the muscle both with and without BMP-2. The gene 
expression in the implant placed on the periosteum is highest at days 2 and 4, with a 
small peak at day 24. When normalized to control femur, there is statistical significance 
at days 2, 4, 12, 16, 24, and 31 between the implant placed on the periosteum and the 
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implant placed in the muscle with BMP-2 (p<0.02). The DBM placed in the muscle 
without BMP-2 shows low expression throughout all time points, and when normalized 
to control femur displays statistical significance at days 4 through 31 (p<0.03).  The 
DBM placed in the muscle with BMP-2 has highest expression at day 2 and day 8, with 
decreased expression at the remaining time points. When normalized to control femur 
this peak at day 8 is statistically significant from the implant placed in the muscle without 
BMP-2 (p=0.0122) as well as the implant placed on the periosteum. When Pax7 was 
normalized to 18s there were less points of significance between experimental groups, 
occurring at days 16, 24, and 31 between the implant places on the periosteum versus the 
implant placed in the muscle with BMP-2 (p<0.02) and between the implants placed in 
the muscle with and without BMP-2 at day 12 (p=0.0369).  
 Prx1 expression is within a close range of values between the three different 
placements. All three experiments peaks respectively at day 8 with a smaller peaks at 
days 16 and 31. These peaks are more visible when compared to control femur, but are 
still present with normalized to 18s. In both normalizations there is a significant 
difference in fold expression at days 2 and 4 between the implant placed on the 
periosteum and the implant placed in the muscle with BMP-2 (p=0.03) and at day 4 
between the implants placed in the muscle with and without BMP-2 (p<0.03). There are 
additional points of significance when normalized to control femur specifically at days 8, 
12, 16, and 31 between the implant places on the periosteum versus the implant placed in 
the muscle without BMP-2 (p<0.02) and at days 24 and 31 between the implants placed 
in the muscle with and without BMP-2 (p<0.03).  
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Chondrogenesis Gene Expression 
 Based on X-ray and MicroCT images, the expected time for chondrogenesis to 
occur was prior to day 12. The gene expression remained consistent with the imaging 
results, with peaks at day 8 indicating chondrogenesis occurring prior to the visualized 
mineralization. Various genes throughout the process of chondrogenesis were chosen for 
Figure 6: qRT-PCR Analysis of Stem Cell Genes when DBM Tissue Placement is Varied and BMP-
2 Added. The graphs display two different normalizations comparing the fold expression between the 
three experimental groups. The graphs on the left display the fold expression when normalized to control 
femur. The graphs of the right display the fold expression when normalized to 18s, also note the 
logarithmic scale on the y-axis. An ANOVA and Wilcox test were preformed between the three 
experimental groups at each time point post-harvest. Significance was determined if p<0.05. “A” signifies 
significance between the implant placed on the periosteum versus muscle with BMP-2,  “B” signifies 
significance between the implant placed on the periosteum versus muscle without BMP-2. “C” signifies 
significance between the implants placed in the muscle with and without BMP-2. “D” signifies 
significance between all three experiential groups.  
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analysis. The earliest marker, Sox9, displayed increased expression at day 8 in both 
normalizations. When normalized to control femur, at days 8, 12, 16 and 24 there was 
significance between the implant placed on the periosteum and the implant placed in the 
muscle without BMP-2 (p<0.03) and between the implants placed in the muscle with and 
without BMP-2 (p<0.03). There was also significance at day 4 between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 
(p=0.0304) and at day 31 between all three experimental groups (p=0.0122). When 
normalized to 18s, Sox9 only displayed significant differences in expression at day 4 
(implant placed on the periosteum versus in the muscle with BMP-2 at p=0.0304), day 24 
(all three experimental groups with p<0.03), and day 31 between the implant placed on 
the periosteum and both implants placed in the muscle with and without BMP-2.  
 NCam1 displayed a peak at day 8 for all three experimental groups as well as a 
subsequent increase in expression at day 16. The implant placed in the muscle with BMP-
2 continued to increase in expression in days 24 through 31 with the other groups 
decreasing. When normalized to control femur, there were significance between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 at 
day 12 (p-0.0216) and day 24 (p=0.0122) and between all three experimental groups at 
day 31 (p<0.03). When normalized to 18s, there was significance between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 and 
between the implants placed in the muscle with and without BMP-2 a day 8 (p<0.03). At 
day 12 there was significance between the implant placed on the periosteum and the 
implant placed in the muscle with BMP-2 (p=0.0216). At day 16, there was significance 
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between the implant placed on the periosteum and both implants placed in the muscle 
with and without BMP-2 (p=0.012). At days 24 and 31 there was significance between 
the implant placed on the periosteum and the implant placed in the muscle with BMP-2 
(p<0.02) and between the implants placed in the muscle with and without BMP-2 
(p=0.0122).  
 Col2a1 is important for the clustering of chondrocytes during chondrogenesis and 
displays the same day 8 peaks, with the largest being in the implant in the muscle with 
BMP-2. When normalized to control femur, there is significance between the implant 
placed on the periosteum and the implant placed in the muscle with BMP-2 at days 8, 16, 
24, and 31 (p=0.0122) and significance between the implants placed in the muscle with 
and without BMP-2 at days 8, 24, and 31 (p<0.02). When normalized to 18s, the same 
groups remain significant at days 24 and 31. There is also significance between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 at 
days 12 and 16 (p=0.0216 and p=0.0122), between the implant placed on the periosteum 
and the implant placed in the muscle without BMP-2 at day 8 (p=0.0348), and between 
the implants placed in the muscle with and without BMP-2 also at day 8 (p=0.0216).  
 Aggrecan (Acan) follows as the next marker for the progression of 
chondrogenesis, again with a peak at day 8 throughout all three experimental groups. 
When normalized to control femur, there was significance between the implant placed on 
the periosteum and the implant placed in the muscle with BMP-2 at day 8 (p=0.0367), 
between all three experimental groups at day 16 (p=0.0122) and between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 
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(p=0.0122) and between the implants placed in the muscle with and without BMP-2 
(p=0.0122) at days 24 and 31. When normalized to 18s, there were similar trends with 
significant differences occurring between the implant placed on the periosteum and the 
implant placed in the muscle without BMP-2 and between the implants placed in the 
muscle with and without BMP-2 at days 8, 12, and 24 (p<0.01). There was also 
significance between all three experimental groups at day 16 (p=0.0122) and between the 
implant placed on the periosteum and the implant placed in the muscle without BMP-2 at 
day 31 (p=0.0122). 
 The final chondrogenetic gene analyzed was Col10a. This was the latest marker 
of chondrogenesis analyzed, and displayed a peak at day 8 for the implant placed on the 
periosteum and the implant placed in the muscle with BMP-2, and a peak at day 12 for 
the implant placed in the muscle without BMP-2.  For both normalizations there was 
significance between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 at days 8 and 16 (p<0.03) and between the implant placed on the 
periosteum and the implant placed in the muscle without BMP-2 (p<0.03) and between 
the implants placed in the muscle with and without BMP-2 at day 24 (p<0.02). The two 
normalizations differed at day 8. When normalized to control femur, there was 
significance between all three experimental groups (p<0.03) compared to the 18s 
normalization where there was significance between the implant placed on the 
periosteum and the implant placed in the muscle without BMP-2 (p=0.0216) and between 
the implants placed in the muscle with and without BMP-2 (p=0.0122).  
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Figure 7: qRT-PCR Analysis of Chondrogenesis Genes when DBM Tissue Placement is Varied and 
BMP-2 Added. The graphs display two different normalizations comparing the fold expression between 
the three experimental groups. The graphs on the left display the fold expression when normalized to 
control femur. The graphs of the right display the fold expression when normalized to 18s, also note the 
logarithmic scale on the y-axis. An ANOVA and Wilcox test were preformed between the three 
experimental groups at each time point post-harvest. Significance was determined if p<0.05. “A” signifies 
significance between the implant placed on the periosteum versus muscle with BMP-2,  “B” signifies 
significance between the implant placed on the periosteum versus muscle without BMP-2. “C” signifies 
significance between the implants placed in the muscle with and without BMP-2. “D” signifies 
significance between all three experiential groups.  
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Angiogenesis Gene Markers 
           Bone is a constantly remodeling organ and is therefore very dependent of having a 
constant source of nutrients. As such, angiogenesis is a necessary component to the 
formation and remodeling of bone. Two markers of angiogenesis, SMA and VE-Cadherin 
were analyzed to determine the fold expression in the three different implants.  
          SMA expression differed between the two normalizations. When normalized to 
control femur, there was a large peak at day 4 in both the implant placed on the 
periosteum and the implant in the muscle with BMP-2. The implant in the muscle without 
BMP-2 has a slight increase at day 8, and all three groups decreased in expression in days 
12 through 31. There was significance between the implants placed in the muscle with 
and without BMP-2 at day 8 (p=0.0216) and days 16 and 31 between the implant placed 
on the periosteum and the implant placed in the muscle without BMP-2 (p=0.0216 and 
p=0.0122) and between the implants placed in the muscle with and without BMP-2 
(p=0.0200 and p=0.0200). When normalized to 18s, there were more instances of 
significance between experimental groups across all time points. Specifically, at days 4 
and 24 between the implant placed on the periosteum and the implant placed in the 
muscle without BMP-2 (p=0.0304 and p=0.0122) and between the implants placed in the 
muscle with and without BMP-2 (p=0.0304 and p=0.0122), days 12 and 16 between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 
(p=0.0216 and p=0.0367) and the implant placed on the periosteum and the implant 
placed in the muscle without BMP-2 (p=0.0216 and p=0.0367). Furthermore, at day 8 
there was significance between all three experimental groups (p<0.02) and at day 31 
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between the implant placed on the periosteum and the implant placed in the muscle with 
BMP-2 (p=0.0216) and between the implants placed in the muscle with and without 
BMP-2 (p=0.0200). 
            VE-Cadherin showed similar trends in both normalizations between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2, with high 
fold expression at days 2 and 8, and a largest decrease at day 4. The implant placed in the 
muscle with BMP-2 displays a different pattern peaking at day 8 and 12, with decreased 
expression at days 2 and 8. When normalized to control femur, there was significance at 
day 8 between the implant placed on the periosteum and the implant placed in the muscle 
with BMP-2 (p=0.0230) and at day 31 between the implant placed on the periosteum and 
the implant placed in the muscle with BMP-2 (p=0.0122) and between the implant placed 
on the periosteum and the implant placed in the muscle without BMP-2 (p=0.0122). 
When normalized to 18s, at day 8 there was significance between all three experimental 
groups with p<0.03. At days 12 and 16 there was significance between the implant placed 
on the periosteum and the implant placed in the muscle without BMP-2 and significance 
between the implants placed in the muscle with and without BMP-2 (p=0.0122). AT day 
24 there was only significance between the implants placed in the muscle with and 
without BMP-2 (p=0.0216). At day 31, there was significance between the implant 
placed on the periosteum and the implant placed in the muscle with BMP-2 (p=0.0122) 
and between the implants placed in the muscle with and without BMP-2 (p=0.0122). 
 
 
	  38 
 
 
Osteogenic Gene Markers 
             From the X-ray and microCT40 analysis, bone formation and mineralization 
became apparent at day 12. To analyze the mineralization further, various Osteogenic 
markers were analyzed. 
 The expression of Runx2 in the implant placed on the periosteum is relatively low 
compared to that of the implant placed in the muscle both with and without BMP-2. With 
BMP-2, the implant placed in the muscle shows increased expression in days 2 through 8, 
Figure 8: qRT-PCR Analysis of Angiogenesis Genes when DBM Tissue Placement is Varied and 
BMP-2 Added. The graphs display two different normalizations comparing the fold expression between 
the three experimental groups. The graphs on the left display the fold expression when normalized to 
control femur. The graphs of the right display the fold expression when normalized to 18s, also note the 
logarithmic scale on the y-axis. An ANOVA and Wilcox test were preformed between the three 
experimental groups at each time point post-harvest. Significance was determined if p<0.05. “A” signifies 
significance between the implant placed on the periosteum versus muscle with BMP-2,  “B” signifies 
significance between the implant placed on the periosteum versus muscle without BMP-2. “C” signifies 
significance between the implants placed in the muscle with and without BMP-2. “D” signifies 
significance between all three experiential groups.  
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maintaining that level through day 31. With no BMP-2, the implant placed in the muscle 
begins with a higher level of expression at day 4 and gradually decreases. For the 
normalization to control femur, there was significance between the implant placed on the 
periosteum and the implant placed in the muscle with BMP-2 at days 8, 12, 16, and 24 
(p<0.01), between the implants placed in the muscle with and without BMP-2 at days 4, 
8, 16, and 24 (p<0.03), and between the implant placed on the periosteum and the implant 
placed in the muscle without BMP-2 at day 4 (p=0.0304). In addition, there was 
significance between all three experimental groups at day 31 (p<0.02). When normalized 
to 18s, there is significance between all three experimental groups at days 8 and 24 
(p=0.0304 and p=0.0367), between the implants placed in the muscle with and without 
BMP-2 at day 8 (p=0.0122), between the implant placed on the periosteum and the 
implant placed in the muscle without BMP-2 at day 16 (p=0.0367), and between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 at 
day 31 (p=0.0367).  
 Osterix appears to have increased expression in the implant placed in the muscle 
with BMP-2 in both normalizations. When normalized to control femur, there was 
significance between the implants placed in the muscle with and without BMP-2 at days 
4 through 31 (p<00.03), between the implant placed on the periosteum and the implant 
placed in the muscle with BMP-2 at days 4, 16, 24, and 31 (p<0.03), and between the 
implant placed on the periosteum and the implant placed in the muscle without BMP-2 at 
days 8 and 12 (p=0.0122). When normalized to 18s, there was significance between the 
implants placed in the muscle with and without BMP-2 at days 8, 12, 24, and 31 
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(p<0.0122), between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 at days 12, 24, and 31 (p=0.0122), and between the implant placed 
on the periosteum and the implant placed in the muscle without BMP-2 at day 8 
(p=0.0058).  
 Osteocalcin continues to follow the trend of osterix, with increased expression in 
the implant placed in the muscle with BMP-2. In all three experimental groups, 
expression does not increase until day 12, which is when mineralization was observed in 
the X-ray and microCT images. The fold expression was very similar between the two 
normalizations, with significance occurring between the implant placed on the 
periosteum and the implant placed in the muscle with BMP-2 and between the implants 
placed in the muscle with and without BMP-2 at days 12, 24, and 31 (p<0.01), and at day 
8 between the implant placed on the periosteum and the implant placed in the muscle 
without BMP-2 (p=0.0058). When normalized to control femur, there is also significant 
difference at day 16 between the implant placed on the periosteum and the implant placed 
in the muscle with BMP-2 (p=0.0122). 
 The final Osteogenic gene, DMP-1 (DMP), is the latest of the markers analyzed. 
It continues to follow the trend of increased expression in the implant placed in the 
muscle with BMP-2. When normalized to control femur, there was significance between 
all three experimental groups at days 12, 16, and 31 (p<0.02), between the implants 
placed in the muscle with and without BMP-2 at days 8 and 24 (p=0.0122 and p=0.0122), 
between the implant placed on the periosteum and the implant placed in the muscle 
without BMP-2 at day 8 (p=0.0149), and at day 24 between the implant placed on the 
	  41 
periosteum and the implant placed in the muscle with BMP-2 (p=0.0122). In the18s 
normalization, there were again significant differences at the later time points. 
Specifically, at days 12, 16, 24, and 31 there was significance between the implant placed 
on the periosteum and the implant placed in the muscle with BMP-2 (p<0.03), at days 12 
and 31 between the implants placed in the muscle with and without BMP-2 (p=0.0122 
and p=0.0122), and at day 24 between the implant placed on the periosteum and the 
implant placed in the muscle without BMP-2 (p=0.012). 
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Figure 9: qRT-PCR Analysis of Osteogenic Genes when DBM Tissue Placement is Varied 
and BMP-2 Added. The graphs display two different normalizations comparing the fold 
expression between the three experimental groups. The graphs on the left display the fold 
expression when normalized to control femur. The graphs of the right display the fold expression 
when normalized to 18s, also note the logarithmic scale on the y-axis. An ANOVA and Wilcox 
test were preformed between the three experimental groups at each time point post-harvest. 
Significance was determined if p<0.05. “A” signifies significance between the implant placed on 
the periosteum versus muscle with BMP-2,  “B” signifies significance between the implant placed 
on the periosteum versus muscle without BMP-2. “C” signifies significance between the implants 
placed in the muscle with and without BMP-2. “D” signifies significance between all three 
experiential groups.  
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BMP-2 Signaling Expression  
 BMP signaling plays an important role in the formation of bone. From our X-ray 
and microCT images, there was no bone formation in the DBM placed within the muscle 
without exogenous BMP-2.  BMP-2, its receptors, and a number of downstream signaling 
molecules were analyzed to see the expression in all three experimental groups in order to 
determine what role BMP-2 plays in ectopic bone formation.  
 The first BMP gene analyzed was BMP-2. BMP-2 was directly mixed with one of 
the implants placed in the muscle and was therefore very important to analyze its 
expression in all three groups. When normalized to control femur, the implant placed on 
the periosteum has the highest fold expression. There was significant difference in fold 
expression between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 at days 2, 4, 8, 16, 24, and 31 (p<0.03). There was also significance 
between the implant placed on the periosteum and the implant placed in the muscle 
without BMP-2 at days 8, 12, 16, 24, and 31 (p<0.03). When normalized to 18s, the 
difference remained between the implant placed on the periosteum and the implant placed 
in the muscle with BMP-2 at days 8, 12, 16, and 31 (p<0.01), but there was also 
significance between the implants placed in the muscle with and without BMP-2 at days 
8, 12, 16, and 31 (p<0.01). At day 8, there was significance between all three 
experimental groups (p<0.03). 
 Following the signaling pathways of BMP-2, the receptors BMPR-1a (Alk3) and 
BMPR-1b (Alk6) were analyzed. BMPR-1a, when normalized to control femur, 
displayed significant difference in expression between the implant placed on the 
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periosteum and the implant placed in the muscle with BMP-2 and between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 at days 4, 
8, 12, 16, and 24 (p<0.03). At days 2 and 31, there was also significance between the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 
(p=0.0304 and p=0.0367). When normalized to 18s there were similar trends of 
significance occurring specifically between the implant placed on the periosteum and the 
implant placed in the muscle with BMP-2 at days 2, 4, 24, and 31 (p<0.03).  The implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 displayed 
significance at days 4 and 24 (p=0.0304 and p=0.0122) and all three experimental groups 
at day 16 (p<0.03).  
 For BMPR-1b, there was a much higher fold expression in the implant placed on 
the periosteum for all times points in both normalizations.  When normalized to control 
femur there was significance between all three experimental groups at days 4 through 31 
(p<0.03) and between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 at day 2 (p=0.0304). When normalized to 18s, there was significance 
between the implant placed on the periosteum and the implants placed in the muscle both 
with and without BMP-2 at days 4 through 31 (p<0.03) and at day 2 between the implant 
placed on the periosteum and the implant placed in the muscle with BMP-2 (p=0.0304). 
The data between the two normalizations suggests that the receptors are more active in 
the implant when placed on the periosteum due to the higher fold expression.  
 BMPR-2 displays the same trends as displayed by receptors 1a and 1b, with 
increased expression in the implant when placed on the periosteum. When normalized to 
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control femur, this is evident due to the significant difference in fold expression between 
the implant placed on the periosteum and both implants in the muscle with and without 
BMP-2 at all time points (p<0.03). The expression differs when normalized to 18s, with 
significance occurring only at day 16 between the implant placed on the periosteum and 
the implant placed in the muscle without BMP-2 (p=0.0122) and between the implants 
placed in the muscle with and without BMP-2 (p=0.0122) and at day 24 between the 
implant placed on the periosteum and the implant placed in the muscle without BMP-2 
(p=0.0122). 
 Downstream in the BMP-2 signaling pathway, ID1, expression was analyzed to 
further attempt to understand the comparative role BMP-2 plays in the growth of DBM in 
the different experimental groups. In both normalizations, ID1 expression is increased in 
the implant placed in the muscle with BMP-2. When normalized to control femur, there 
was significance between the implant placed on the periosteum and the implant placed in 
the muscle with BMP-2 and between the implants placed in the muscle with and without 
BMP-2 at days 4, 24, and 31 (p<0.03). At days 8 and 12 there was significance between 
the implant placed on the periosteum and the implant placed in the muscle without BMP-
2 and between the implants placed in the muscle with and without BMP-2 (p<0.01). At 
day 16 there was significance between all three experimental groups (p=0.0122). When 
normalized to 18s there was only significant differences at day 24 between the implant 
placed on the periosteum and the implant placed in the muscle with BMP-2 (p=0.0122) 
and at day 31 between the implant placed on the periosteum and the implant placed in the 
muscle with BMP-2 (p=0.0122) and between the implant placed on the periosteum and 
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the implant placed in the muscle without BMP-2 (p=0.0367).  
 Noggin, a BMP-2 antagonist, was analyzed and displayed very similar results to 
that of the BMP-2 receptors, with an increase in expression in the implant place on the 
periosteum at all time points. When normalized to control femur, there was significance 
between all three experimental groups at all time points (p<0.03). When normalized to 
18s, there was significance between the implant placed on the periosteum and the implant 
placed in the muscle both with and without BMP-2 at days 4, 8, 16, 24, and 31 (p<0.03) 
with significance between all three experimental groups at day 12 (p=0.0122). 
 The final gene analyzed with the BMP-2 signaling genes was MSTN. Although it 
is primarily a marker in skeletal muscle, it is a member of the TGF-β super family along 
with BMPs, and was therefore analyzed within this category. When normalized to control 
femur, MSTN displays a large peak at day 24 in the implant placed on the periosteum, 
with overall increased expression throughout all time points. At days 8, 16, 24, and 31 
there was significance between the implant placed on the periosteum and the implant 
placed in the muscle with BMP-2 (p<0.01). At days 12 and 24 there was significance 
between the implant placed on the periosteum and the implant placed in the muscle 
without BMP-2 (p=0.0122). At days 8 and 24 there was significance between the 
implants placed in the muscle with and without BMP-2 (p=0.0122).  When normalized to 
18s, the fold expression was much closer between experimental groups with significance 
only occurring at two time points. At day 12, there was significance between the implant 
placed on the periosteum and the implant placed in the muscle without BMP-2 
(p=0.0367) and between the implants placed in the muscle with and without BMP-2 
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(p=0.0216). At day 24, there was significance between the implant placed on the 
periosteum and the implant placed in the muscle with BMP-2 (p=0.0200) and between 
the implants placed in the muscle with and without BMP-2 (p=0.0200). 
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Figure 10: qRT-PCR Analysis of BMP-2 Signaling Genes when DBM Tissue 
Placement is Varied and BMP-2 Added. The graphs display two different 
normalizations comparing the fold expression between the three experimental groups. 
The graphs on the left display the fold expression when normalized to control femur. 
The graphs of the right display the fold expression when normalized to 18s, also note 
the logarithmic scale on the y-axis. An ANOVA and Wilcox test were preformed 
between the three experimental groups at each time point post-harvest. Significance was 
determined if p<0.05. “A” signifies significance between the implant placed on the 
periosteum versus muscle with BMP-2,  “B” signifies significance between the implant 
placed on the periosteum versus muscle without BMP-2. “C” signifies significance 
between the implants placed in the muscle with and without BMP-2. “D” signifies 
significance between all three experiential groups.  	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DISCUSSION 
 
Effect of Tissue Site of DBM Implantation on Extent of Bone Formation   
 
 
 The DBM placed on the periosteal surface of the femur and the DBM implanted 
in the muscle with BMP-2 both induced ectopic bone formation while the DBM in the 
muscle with no additional BMP-2 did not.  While throughout the time course, the BV of 
the implant in the muscle with BMP-2 does increase, most noticeably between days 24 
and 31, the BV of the implant placed on the periosteum was consistently and significantly 
greater than that of the implant placed in the muscle with BMP-2 at earlier times.   The 
TV of the implant in the muscle with BMP-2 was consistently and significantly greater 
than that of the implant on the periosteum. This BV/TV comparison suggests that while 
the implant in the muscle with BMP-2 is larger in size, it does not mineralize to the extent 
that the implant on the periosteum does. Figure 4 supports this with a visualization of 
both the size and relative densities of the implants. It appears that the implant in the 
muscle with BMP-2 increases in size, but forms a shell with the most mineralization 
occurring in the outer portion of the implant. Thus the implant on the periosteum while 
having an overall smaller TV is smaller is more compact and forms a more uniform 
volume of mineralized tissue in the new bone that is formed.      
 There was no detectable mineralization in the implant in the muscle without 
BMP-2. This suggests that BMP-2 is required for the induction of bone formation.  This 
conclusion remains consistent with other studies, such as Jang et al., where it was 
concluded that activating DBM with recombinant BMP-2 enhanced the osteogenesis. 
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Further analysis using qRT-PCR was required in order to better determine the 
mechanisms leading to the recruitment, development, and growth of the implant in the 
varying experimental groups.   
 
Comparison of Various Means of Evaluating Gene Expression Levels.  
 
 When examining the mRNA expression levels multiple approaches were taken to 
normalize the qRT-PCR results.  Normalization was either as a fold to the base line level 
in bone or simply to the genes expression level per ratio to 18S rRNA .  A third 
assessment of the baseline levels of each gene in muscle was also made. By normalizing 
to 18s, the gene expression is being normalized to the number of cells in the specific 
sample. This is based on the assumption that rRNA levels are constant per cell.  This 
normalization is valuable in comparing directly between the experimental groups to 
determine where expression was the highest and at what time point and providing a direct 
comparisons of the genes expression in the different tissues.  Conversely when assessed 
as a fold of the bone this provides a means of showing the levels of induction of the 
individual genes over that seen in cells in quiescent bone.  Finally by accessing the 
baseline in muscle we can determine if the observed genes appeared to be expressed de 
novo in this tissue.  Such comparisons are very useful in determining differences in the 
stem cell associated markers and possibly populations of stem cells recruited to the 
different sites.  These assessments are also useful in assessing the overall quantities of 
new skeletal cell induction and times of these cells differentiation.   
 
	  51 
Implant Placement Alters Stem Cell Gene Expression 
 
             Sox2, Oct4, and Nanog are three of the earliest markers and are associated with 
embryonic stem cells (Go et al. 1147). The qRT-PCR results, for both normalizations, 
display a distinct pattern of expression of these genes between the DBM placed on the 
periosteum versus the DBM placed in the muscle with and without BMP-2.  The day 2 
increase in the implant on the periosteum is sharply contrasted to the implants in the 
muscle. This would suggest that there may be an extremely early population of stem cells 
in the periosteum that is recruited that contributes to bone development in response to the 
DBM placement on the periosteum. The implants in the muscle with and without BMP-2 
showed no early induction with their levels largely remaining the same across the whole 
time course.   
          The osteochondrogenetic marker, Gremlin, displays two different patterns of 
expression when normalized to control femur versus normalized to 18s. When 
normalized to control femur, there is a major peak at day 8 in the implant in the muscle 
without BMP-2.  Since Gremlin defines a population of stem cells that generate 
osteoblasts and chondroblasts, it could be inferred that this peak it related to an increase 
chondrocyte activity (Worthley 269). The DBM in the muscle with no BMP-2 does not 
induce mineralized bone, therefore the peak could be an indication that the implant is 
undergoing chondrogenesis and recruiting cells to proceed with osteogenesis, but it 
unable to continue with the process. When normalized to 18s, expression is increase in 
both implants in the muscle relative to the implant on the periosteum. The largest 
expression is seen in the implant in the muscle with BMP-2, specifically in days 12 
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through 31. During this time, increased mineralization of the implant in the muscle with 
BMP-2 is occurring, suggesting that there would be an increase in Osteogenic cell 
activity supported by the rise in Gremlin signaling.  
            The normalizations for Prx1 varied for the implant in the muscle with BMP-2. 
When normalized to control femur, all three experimental groups follow similar patterns 
and levels of expression peaking at day 8 and 16. These peaks correlate with the time in 
which chondrogenesis appears to be occurring in the implants. Since Prx1 is involved 
with the proliferation and differentiation of chondrocytes, this peak further supports 
chondrogenesis is occurring at day 8. (Berge et al. 3831). This also suggests that the 
process of chondrocyte signaling and recruitment is consistent between experimental 
groups. The groups vary between days 24 and 31 when there is a large increase in 
expression in the implant in the muscle with BMP-2. Further analysis of the histology 
could indicate if there is a reservoir of Prx1 positive cells in the implant at these later 
time points. When normalized to 18s, the expression changes drastically for the implant 
in the muscle with BMP-2, specifically in relation to the other experimental groups and at 
later time points.  Labeling and comparing Prx1 positive cells between all three 
experimental groups, specifically at day 31, could help to better determine which 
normalization is a better representation of the population of cells present.  
            Pax7, identified as a myogenic stem cell, interacts with satellite cells in the 
muscle to cause proliferation (Morgan et al. 1151). Contrary to our initial expectations, 
Pax7 expression is higher in the DBM on the periosteum versus in the muscle (both with 
and without BMP-2) in both normalizations. This could be a result of two different 
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mechanisms working depending on the location of the implant. Furthermore, the implant 
on the periosteum could have increased expression because it is recruiting cells from the 
muscle. The implants in the muscle could require less of a signal due to the closer 
proximity to Pax7 responsive cells.  
 
Cartilage Gene Expression and Endochondrial Ossification 
 The model of endochondral ossification, with chondrogenesis occurring prior to 
ossification appears to be present in all three of the experimental groups.  Sox9, the gene 
responsible for chondrocyte lineage commitment from mesenchymal cells (Provot et al. 
659) shows significant increase in all three experimental groups at day 8. Col2a1, Acan, 
and Col10a are specific late cartilage markers, which are used to assess the progression 
of chondrogenesis, specifically in endochondral ossification (Mwale et al. 1791). The 
three markers, again, increase at day 8 in all three experimental groups. The peak 
indicates chondrocyte commitment and differentiation, is at day 8. This is consistent with 
our X-ray and MicroCT data where mineralized tissue first appears at day 12, indicating 
cartilage would be developing in the previous time points. The qRT-PCR graphs all 
decrease steadily from days 8 to day 31, which is the time when osteogenesis would be 
occurring.  
 Of the chondrogenic markers, NCam1 is the only gene, which slightly 
differentiates from the pattern of peak expression at day 8.  The expression is relatively 
high at both day 4 and day 8 followed by slight decreases though day 31. NCam1, a 
member of the immunoglobulin superfamily, is involved in cell-to-cell interaction as well 
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as matrix interactions during development (Wu et al. 577). The declining trend remains 
consistent with the results of Wu et al., observing a decline in NCam1 expression as 
condensed pre-chondrocytes differentiates into chondrocytes (Wu et al., 577). The gene 
expression remains consistent with expectation based on the microCT images and the 
process of endochondrial ossification. While the level of expression is higher in the 
muscle, both placements follow similar trends.  
 
Angiogenesis Expression 
 α-Sma expression, when normalized to control femur, is increased at days 2 and 4 
in the implant placed on the periosteum and the implant placed in the muscle with BMP-2 
compared to the implant placed within the muscle without BMP-2. By day 8, the 
expression decreases and proceeds to follow the same pattern and level of expression as 
that of the muscle implant both with and without BMP-2. α-Sma is a marker of 
myofibroblasts. The differentiation of myofibroblasts leads to the synthesis of smooth 
muscle cells, which make up blood vessels (Abdalla et al.). The rise of SMA in the 
implant placed on the periosteum and the implant placed in the muscle with BMP-2 could 
relate to their abilities to mineralize at later time points. Increased α-Sma suggests the 
development of vessels that would be vital for the development of bone. The implant in 
the muscle with BMP-2 has lower fold expression, and does not develop and mineralize 
into bone. The normalization to 18s differs in that the expression in the muscle without 
BMP-2 is increased. The expression could be increased as an attempt for the implant to 
recruit smooth muscle cells to develop in order to form a blood source for implant. When 
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it is unable to do so, the expression decreases as seen in days 12 through 16, and the 
implant is unable to mineralize.  
 VE-Cadherin expression, when normalized to control femur, is very similar in the 
implant on the periosteum and in the muscle with no BMP-2. The implant in the muscle 
with BMP-2 has the same relative levels of expression, but follows a different pattern 
throughout the initial time points. It remains consistently lower than both other 
experimental groups until day 31 where it increases. VE-cadherin’s primary role is in the 
adhesion of endothelial cells. For vascularization, they play a crucial role in embryonic 
angiogenesis (Vestweber 223). As such, the increase at days 2 and 8 could correlate with 
increasing vascularization to assist in the chondrogenesis that is also occurring at day 8. 
The normalization to 18s displays very comparable levels between the three experimental 
groups with the lowest expression being in the muscle with no BMP-2. Again this 
suggests that the implant in the muscle with no BMP-2 was not able to induce the 
differentiation of myofibroblasts, and therefore the signaling for adhesion would be 
decreased.  
 
Bone Gene Expression 
 Runx2 is an osteoblastic transcription factor that stimulates the differentiation of 
skeletal myocytes into osteoblasts (Gersbach 874).  It has also been demonstrated that 
Runx2 has a significant role during chondrocyte hypertrophy in endochondral ossification 
(Kim et al. 2). The gene expression of Runx2 suggests that the implant in the muscle 
without BMP-2 attempts to induce chondrocyte hypertrophy and differentiation of 
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myocytes through the high expression at day 4. The expression decreases through day 8, 
as the implant is unable to induce the differentiation to form cartilage. The implant in the 
muscle with BMP-2 shows a similar pattern to that of the periosteal implant, but with 
higher fold expression. This higher expression, especially at the later time points could 
account for the muscle implant with BMP-2’s increase in bone volume in days 24 
through 31.  
 Osterix expression remains very consistent between the two normalizations with 
the highest expression being seen in the implant in the muscle with BMP-2 and lower 
expression in the muscle without BMP-2. The increase in the implant in the muscle with 
BMP-2 as compared to the implant on the periosteum correlates with the slower 
mineralization of the implant in the muscle versus periosteum. At day 16, the implant on 
the periosteum has already reached  near its maximum bone volume while the implant in 
the muscle with BMP-2 is continuing to mineralize at a slower rate. As a result, the 
expression remains higher in the muscle with BMP-2 while the implant on the periosteum 
decreases at day 16. 
 Osteocalcin, a small protein secreted by osteoblasts, is a marker for the 
mineralization of bone (Caetano-Lopes et al. 107). Osteocalcin activity is increased in the 
implant in the muscle with BMP-2 specifically in days 16 through 31. The bone volume 
measurements follow this trend as the implant in the muscle with BMP-2 increases in 
volume in the later time points. This expression differs from both the DBM on the 
periosteum as well as the implant in the muscle with no BMP-2, which show minimal 
expression.   
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 DMP1, dentin matrix protein 1, is associated with the later stages of 
skeletalgenesis, specifically the mineralization of bone (Sun et al. 199). In the 
normalization to control femur, the increased expression of DMP1 in both the DMB 
implant in the muscle with BMP-2 and the implant on the periosteum correlate to bone 
development in both cases. The expression is higher in the implant in the muscle with 
BMP-2, which could a result of the slower bone formation. Expression is increased in 
days 16 through 31 in an attempt to catch up to the developing periosteal implant. The 
lack of expression in the implant in the muscle with no BMP-2 is supported by the lack of 
bone formation seen in the MicroCT and X-ray analyses. In the normalization to 18s, the 
same trends remain, except at day 24 when the implant in the muscle without BMP-2 
increases above that of the implant in the periosteum. This increase is different than what 
we expected, as there was no mineralized bone detected in the implant in the muscle 
without BMP-2.  
 
BMP-2 Signaling Expression Limited to the Periosteum  
 BMP-2 signaling follows very comparable expression throughout the signaling 
pathway. In general, for BMP-2 in the periosteum, there is an increased level of 
expression through the entire time course as compared to in the muscle where there is 
essentially no expression. This pattern continues through the BMPR1a, BMPR1b and 
BMPR2, but there is a much larger fold change in BMPR1b. The BMP-2 signaling in the 
implant on the periosteum is consistent with the development and mineralization of the 
implant. It is interesting that the implant in the muscle has low fold expression even when 
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BMP-2 is added. The implant in the muscle with BMP-2 may have a reduced need to 
signal endogenous BMP-2 resulting in the decreased expression.  
 Noggin increases in the periosteum at day 24 when BMP-2 shows declining 
expression. This differs from Noggin’s expression in the muscle with BMP-2 where there 
is comparable expression throughout the time course. As a result, Noggin’s role as a 
BMP-2 antagonist appears to be important in the periosteal implant, having less of an 
affect in the muscle. Expression of ID1 is increased in days 2 through 4, steadily 
decreasing and remaining constant in days 12 through 31 in the implant in the muscle 
with BMP-2. This differs from the implant on the periosteum and the implant in the 
muscle with no BMP-2 where there is very low expression. MSTN, a member of the 
TGF-β superfamily that has an important role in negatively regulating muscle growth, 
peaks in all three groups (Rios et al. 993). In the implant on the periosteum and implant 
in the muscle without BMP-2, there is a peak at day 24 with a higher expression in the 
implant on the periosteum. This peak correlates with noggin, which also peaks at day 24 
in the implant on the periosteum. The implant in the muscle with BMP-2 does not reach 
the same fold expression and appears to have relatively low expression. This correlates 
with Lui et al. who reported that muscle genes are down regulated in response to BMPs 
(Lui et al. 73). 
 
Conclusion & Future Work 
 The X-ray and MicroCT images provide support that DBM is a viable option for 
bone formation in vivo. Based on the gene expression, a model of endochondral 
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ossification is accepted in the formation of ectopic bone, with a peak in chondrogenetic 
expression prior to osteogenesis.  
 The gene expression showed a large degree of variation between the different 
placements of DBM in the muscle and on the periosteum. Based on microCT analysis, 
DBM in the muscle required BMP-2 in order to induce bone formation. The final volume 
and distribution of the bone appears to differ between the two placements. When placed 
on the periosteum, the total volume is much smaller, but the overall bone volume is 
increased. This suggests a smaller, more solidified bone formation. The implant in the 
muscle with BMP-2 has a decreased bone volume, but a significantly larger total volume. 
In future analysis, the bone volume could be determined for the core of the implant 
versus the exterior in order to determine the density and distribution of the bone 
formation in the muscle with BMP-2.  
 The gene expression differed between the implant on the periosteum and the 
implant in the muscle with and without BMP-2 added. The implant on the periosteum and 
the implant in the muscle with BMP-2 were able to induce bone formation while the 
implant in the muscle without BMP-2 was not. This proved interesting, as all three 
groups had some degree of expression of the early stem cell markers. The patterns of 
expression differed between the implant on the periosteum and the implants in the muscle 
suggesting the preliminary mechanisms leading to the recruitment of stems cells and 
differ between the two tissue locations. It appears that when placed on the periosteum, the 
implant is able to induce early stem cell markers, whereas the implant in the muscle with 
BMP-2 is developing through an alternative mechanism. All three experimental groups 
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were able to induce the formation of cartilage as seen in the cartilage gene markers. 
When the cartilage was progressing to bone, the DBM in the muscle without BMP-2 was 
able to signal, but the cells were unable to progress. The DBM in the muscle with BMP-2 
and the implant on the periosteum continued to ossify and mineralize to detectable 
volumes of bone.  
 Overall, this study provided further information into the effect of tissue placement 
on the quality of progression of bone formation. The most optimal implant growth 
occurred when placed directly on the periosteum, but growth was inducible in the muscle 
when BMP-2 is added. The placement of the implant in different tissues not only affected 
the size and volume of the implant, but also the gene expression. For stem cell 
recruitment, it is evident that different mechanisms are occurring to progress bone 
formation in the different tissue locations. Due to the low expression from the stem cell 
genes analyzed, future studies are needed to determine what mechanism is occurring 
when the implant is placed in the muscle. Specific indicator mice can be used to identify 
cells where stem cell makers are expressed, for example Prx1, Pax7, and Sox2 and follow 
their temporal and spatial movement. For the analysis of the effect of BMP-2, it is 
concluded that the addition of BMP-2 is required for the formation of bone. When placed 
on the periosteum, endogenous BMP-2 is present leading to the development and 
progression of the implant to form bone. When placed in the muscle, the implant 
progressed to form bone only with the addition of BMP-2. The gene expression supported 
this with increased expression in the implant placed on the periosteum and in the muscle 
with BMP-2. To further analyze the role BMP-2 plays in DBM’s ability to recruit stem 
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cells versus promote differentiation in different tissue locations, noggin, a BMP-2 
antagonist, can be added to the DBM and placed on the periosteum and in the muscle. 
This would further illustrate whether DBM when placed on the periosteum retains its 
ability to induce various stem cell associated genes or whether this effect is dependent on 
BMP-2. The question of retention of BMP2 in DBM and its spatial presentation at 
implant sites will further be analyzed by quantum dots used tag BMP-2 within the various 
DBM implant sites.  	  
  
	  62 
REFERENCES 
Abdalla, M., Goc, A., Segar, L., & Somanath, P. (2013). Akt1 mediates α-Smooth 
 Muscle Actin Expression and Myofibroblast Differentiation via Myocardin and 
 Serum Response Factor. Journal of Biological Chemistry, 288(46), 33483–
 33493. 
Abou-Khalil, Rana, Frank Yang, Shirley Lieu, et al. Role of Stem Cells in Skeletal 
 Muscle Development, Regeneration, Repair, Aging and Disease. Frontiers in  
Aging Neuroscience.  AlphaMed Press, 24 Sept. 2014. Web. 15 Mar. 2015. 
Alden, Tord D., Elisa J. Beres, Jeffrey S. Laurent, Johnathan A. Engh, Subinoy Das, 
Scott D. London, John A. Jane, Jr., Sarah B. Hudson, and Gregory A. Helm 
(2000). The Use of Bone Morphogenetic Protein Gene Therapy in Craniofacial 
Bone Repair. Journal of Craniofacial Surgery, 11(1), 24–30. 
Amin, Shreyasee. Osteoporosis. Osteoporosis | American College of Rheumatology | 
ACR. American College of Rheumatology, Mar. 2012. Web. 03 Feb. 2015. 
Bae, Hyun, Li Zhao, Dagny Zhu, Linda E. Kanim, Jeffrey C. Wang, and Rick B. 
Delamarter (2010) . Variability Across Ten Production Lots of a Single 
Demineralized Bone Matrix Product. Journal of Bone and Joint Surgery, 92(2), 
427–35. doi: 10.2106/JBJS.H.01400. 
Bais, M., J. McLean, P. Sebastiani, M. Young, N. Wigner, T. Smith, D. N. Kotton, T. A. 
Einhorn, and L. C. Gerstenfeld (2009). Transcriptional Analysis of Fracture 
Healing and the Induction of Embryonic Stem Cell-Related Genes. PLoS One, 
4(5):e5393. doi: 10.1371/journal.pone.0005393. 
Bragdon, Beth, O. Moseychuk, S. Saldanha, D. King, J. Julian, and A. Nohe (2011). 
Bone Morphogenetic Proteins: A Critical Review.  Cellular Signaling, 23(4), 
609–20. doi: 10.1016/j.cellsig.2010.10.003 
Caetano-Lopes, Jonana, Canhao, Helena, Fonseca, Joao Eurico (2007). Osteoblasts and 
Bone Formation. Acta Reumatológica Portuguesa, 32, 103–110. 
Carreira, A.C., F. H. Lojudice, E. Halcsik, R. D. Navarro, M. C. Sogayar, and J. M. 
 Granjeiro (2014). Bone Morphogenetic Proteins: Facts, Challenges, and Future 
 Perspectives. Journal of Dental Research, 93(4), 335–45. 
Chen, D., M. Zhao, and GR Mundy (2004). Bone Morphogenetic Proteins. Growth 
Factors, 22(4), 233–41. 
	  63 
Crombrugghe, Benoit De, Véronique Lefebvre, and Kazuhisa Nakashima (2001). 
Regulatory Mechanisms in the Pathways of Cartilage and Bone Formation. 
Current Opinion in Cell Biology, 13(6), 721–28. 
"DBX® Demineralized Bone Matrix." DBX® Demineralized Bone Matrix. DePuy 
Synthesis Companies, 2004. Web. 04 Feb. 2015. 
http://www.synthes.com/sites/NA/Products/Biomaterials/BoneVoidFillersSpine/P
ages/DBX_Spine.aspx 
Gersbach, C. A., J. M. Le Doux, R. E. Guldberg, and A. J. Garcia (2006). Inducible 
Regulation of Runx2-stimulated Osteogenesis. Gene Therapy, 13(11), 873–82. 
"Grafton DBM Clinical Overview." (2008): 1–12. BioHorizons. BioHorizons Implant 
 Systems, 2008. Web. 4 Feb. 2015. 
Gruskin, Elliott, Bruce A. Doll, F. W. Futrell, John P. Schmitz, and Jeffrey O. Hollinger 
(2012). Demineralized Bone Matrix in Bone Repair: History and Use. Advanced 
Drug Delivery Reviews, 64(12), 1063–77. doi: 10.1016/j.addr.2012.06.008.  
Hollinger, Jeffrey O. (2005). Bone Dynamics: Morphogenesis, Growth, Modeling, and 
Remodeling. In Jay R. Lieberman and Gary E. Friedlaender (eds.) Bone 
Regeneration and Repair: Biology and Clinical Applications. (pp. 1– 20). 
Totowa, NJ: Humana Press. 
Holt, Dolly J., and David W. Grainger. Demineralized Bone Matrix as a Vehicle for 
Delivering Endogenous and Exogenous Therapeutics in Bone Repair. Advanced 
Drug Delivery Reviews, 64(12), 1123–8. doi: 10.1016/j.addr.2012.04.002.  
Jang, Yoon Seok, Choi, Cheol, Cho, Young, et al. (2014). Recombinant human BMP-2 
 enhances osteogenesis of demineralized bone matrix in experimental mastoid 
 obliteration. Acta Oto-Laryngologica, 134, 785–790. Web. March 2015. 
Kini, Usha, and B. N. Nandeesh (2012). Physiology of Bone Formation, Remodeling, and 
Metabolism. In I. Fogelman, G. Gnanasegaran, and H. van der Wall (eds.), 
Radionuclide and Hybrid Bone Imaging. (pp. 29–57). Berlin, Heidelberg: 
Springer-Verlag. 
Lee, Kenneth J. H., Johnathan G. Roper, and Jeffrey C. Wang (2005). Demineralized 
Bone Matrix and Spinal Arthrodesis. Spine Journal, 5(6 Suppl.), 217S–223S. 
Mackie, E. J., Ahmed L. Tatarczuch, K. S. Chen, and M. Mirams (2008). Endchondrial 
 Ossification: How Cartilage Is Converted into Bone in the Developing Skeleton." 
 International Journal of Biochemistry and Cell Biology 40, 46–62. 
	  64 
Merino, R., J. Rodriguez-Leon, D. Marcias, Y. Ganan, N. Economides, and J. M. Hurle 
(1999). The BMP Antagonist Gremlin Regulates Outgrowth, Chondrogenesis and 
Programmed Cell Death in the Developing Limb. Development, 126(23), 5515-
22. Web. 09 Feb. 2015. 
Miclau, Theodore, Richard A. Schneider, B. F. Eames, and Jill A. Helms (2005). 
Common Molecular Mechanisms Regulating Fetal Bone Formation and Adult 
Fracture Repair.  In Jay R. Lieberman and Gary E. Friedlaender (eds.) Bone 
Regeneration and Repair: Biology and Clinical Applications. (pp. 45–55). 
Totowa, NJ: Humana Press. 
Moucha, Calin S., and Thomas A. Einhorn (2005). Bone Morphogenetic Proteins and 
Other Growth Factors to Enhance Fracture Healing and Treatment of Nonunions.  
In Jay R. Lieberman and Gary E. Friedlaender (eds.) Bone Regeneration and 
Repair: Biology and Clinical Applications. (pp. 169–194). Totowa, NJ: Humana 
Press. 
Mwale, F., Stachura, D., Roughley, P. and Antoniou, J. (2006), Limitations of using 
 aggrecan and type X collagen as markers of chondrogenesis in mesenchymal stem 
 cell differentiation. Journal of Orthopedic Research, 24: 1791–1798. 
 doi: 10.1002/jor.20200  
“Physical Fields.” Physical Fields-OrthoInfo - AAOS. American Academy of 
 Orthopaedic Surgeons, Oct. 2002. Web. 03 Feb. 2015 
Pietrzak, William S., Stephen V. Perns, Joshua Keyes, Jennifer Woodell-May, and 
Nicholas M. McDonald (2005). Demineralized Bone Matrix Graft: A Scientific 
and Clinical Case Study Assessment. Journal of Foot and Ankle Surgery, 44(5), 
345–353. Web. 6 Feb. 2015 
Provot, S., and E. Schipani (2005). Molecular Mechanisms of Endochondral Bone 
Development.  Biochemical and Biophysical Research Communications, 328(3), 
658–665. Web. 30 Jan. 2015. 
Rios, Ramon, Carneiro, Isabel, Arce, Victor M., Devesa, Jesus (2002). Myostatin is an 
inhibitor of myogeneic differentiation. American Journal of Physiology. Cell 
Physiology, 282(5), C993–C999. Web. 15 Feb 2015. 
Sun, Y., Li, C., Ma, S., Zhou, J., Zhang, H., Feng, J. Q., Qin, C. (2011). Roles of DMP1 
Processing in Osteogenesis, Dentinogenesis and Chondrogenesis. Cells, Tissues, 
Organs, 194(2–4), 199–204. Web. 18 Mar 2015. 
Vestweber, Dietmar (2008). VE-Cadherin: The Major Endothelial Adhesion Molecule 
 Controlling Cellular Junctions and Blood Vessel Formation. Arteriosclerosis, 
 Thrombosis, and Vascular Biology, 28(2), 223–232. Web. 13 Feb. 2015. 
	  65 
Worthley, Daniel, Churchill, Michael, et al. (2015). Gremlin 1 Identifies a Skeletal Stem 
Cell with Bone, Cartilage, and Reticular Stromal Potential. Cell, 160(1–2), 269–
284. doi: 10.1016/j.cell.2014.11.042. Web. 15 Mar. 2015. 
Wu, Ling, Carolina Bluguermann, Levon Kyupelyan, Brooke Latour, Stephanie 
Gonzalez, Saumya Shah, Zoran Galic, Sundi Ge, Yuhua Zhu, Frank A. 
Petrigliano, Ali Nsair, Santiago G. Miriuka, Xinmin Li, Karen M. Lyons, Gay M. 
Crooks, David R. McAllister, Ben Van Handel, John S. Adams, and Denis 
Evseenko (2013). Human Developmental Chondrogenesis as a Basis for 
Engineering Chondrocytes from Pluripotent Stem Cells." Stem Cell Reports, 1(6), 
575–589. doi: 10.1016/j.stemcr.2013.10.012. Web. 13 Feb. 2015. 
Zhu, Wei, Jaehon Kim, Christina Cheng, Bernard A. Rawlins, Oheneba Boachie-Adjei, 
Ronald G. Crystal, and Chisa Hidaka. Noggin Regulation of Bone Morphogenetic 
Protein (BMP) 2/7 Heterodimer Activity in Vitro. Bone, 39(1), 61–71. Web. 9 
Feb. 2015.
	  66 
CURRICULUM VITAE 
 
ALEXANDRA FEMIA 
 
914 Beacon St., Boston MA 02215 
alfemia@bu.edu  |   (716) 573-4908  |   Year of Birth: 1991 
------------------------------------------------------------------------------------------------------------ 
EDUCATION 
------------------------------------------------------------------------------------------------------------ 
Boston University School of Medicine | Boston, MA | September 2013 – May 2015 
Master of Science in Medical Sciences    
 Relevant Coursework: Human Physiology, Biochemistry, Histology, Pathology, 
 Biomedical Informatics, Biostatistics 
 
College of the Holy Cross | Worcester, MA | August 2009 – May 2013 
Bachelor of Arts in Mathematics  
Relevant Coursework: Introduction to Biology, Organic Chemistry, General 
Chemistry, Physics, Calculus, Multivariable Calculus, Medical Ethics 
Directed Project: Modeling Negative Curvature of Beta Sheet Proteins 
Honors: Dean’s List in 2012 and 2013 
------------------------------------------------------------------------------------------------------------ 
RESEARCH & WORK EXPERIENCE 
------------------------------------------------------------------------------------------------------------ 
Boston University School of Medicine: Department of Orthopaedic Surgery 
Boston, MA | July 2014 – Current | Graduate Researcher 
•  Completed a master’s thesis pertaining to the role of bone morphogenetic protein 
2 (BMP-2) in ectopic bone growth in muscle 
 
University of Buffalo: Orthopaedics and Sports Medicine 
Buffalo, NY | June 2013 – August 2013 | Undergraduate Literature Reviewer    
• Performed a literature review on allografts versus autographs in elbow instability 
• Familiarized myself with research techniques, various databases, and relevant 
literature   
 
Massachusetts General Hospital: Department of Clinical Cardiology 
Boston, MA | May 2012 – August 2012 | Research Assistant     
• Prepared, aliquoted, and handled blood samples for a multisite study  
• Enrolled patients, collected specimens, and performed data entry for BIONICS-
Heart Failure study  
• Created a database for the North South East West Study 
• Attended a certification course in phlebotomy  
• Observed patients the Cardiac Intensive Care Unit 
 
	  67 
Excelsior Orthopaedics 
Buffalo, NY | May 2011 – August 2011 | Student Shadow   
• Shadowed doctors, physicians assistants, and physical therapists 
• Observed several surgical procedures 
 
------------------------------------------------------------------------------------------------------------ 
RESEARCH SKILLS 
------------------------------------------------------------------------------------------------------------ 
• Laboratory mouse handling including intraperitoneal and subcutaneous injections  
• Surgical techniques including anesthesia and suturing  
• X-Ray imaging and development 
• Scanning using a MicroCt40 and image analysis  
• Extensive experience with RNA extraction, cDNA production, and qRT-PCR  
• Knowledge of agarose Gel Electrophoresis running and analysis  
• Experience with Microsoft PowerPoint and Excel, as well as the presentation of 
scientific findings  
• Proficient in MATLAB  
------------------------------------------------------------------------------------------------------------ 
LEADERSHIP & VOLUNTEER ACTIVITIES 
------------------------------------------------------------------------------------------------------------ 
Massachusetts General Hospital: Patient Escort Services  
Boston, MA | March 2014 – Current | Volunteer  
• Assist patients entering and being discharged from the hospital 
• Work on a team with peers to coordinate the successful transport of patients 
 
American Mathematical Society: Spring Eastern Sectional Meeting  
Chestnut Hill, MA | April 2013 | Student Organizer and Presenter  
• Presented on Modeling Negative Curvature of Beta-Sheet Proteins  
• Reviewed undergraduate submissions for acceptance to the conference 
• Chaired and ran presentations throughout the session 
 
College of the Holy Cross: Student Programs for Urban Development (SPUD) 
Worcester, MA | May 2012 – May 2013 | Educational Opportunities Intern 
• Accountable for seven volunteer sites, seven program directors, and over a 
hundred volunteers 
• Worked with campus groups and program directors to promote social justice and 
action within the Holy Cross community 
• Developed teamwork and organizational skills working intimately with four 
fellow interns to coordinate the largest student organization on campus 
 
City View Afterschool Program 
Worcester, MA | September 2009 – May 2013 | Program Director and Volunteer  
• Volunteered weekly with elementary and middle school children 
	  68 
• Provided students with one-on-one attention for both tutoring and games 
• Transported thirty volunteers to and from the site 
 
Students Helping Children Across Borders, Inc.: Working for Worcester  
Worcester, MA | September 2012 – May 2013 | Site Coordinator  
• Developed and implemented a city-wide project to build community 
infrastructure for Worcester’s families and children  
• Partnered with local business and colleges to execute a city wide effort 
• Coordinated and planned a cafeteria remodeling and grounds clean up of Elm 
Park Elementary School  
 
College of the Holy Cross: Arrupe Immersion Program   
Tanzania | January 2012   
• Visited Project Partners of International Partners in Mission  
• Socialized with orphans of HIV/AIDS and Malaria victims at the Mgolole 
children’s orphanage 
• Learned the history and culture of Tanzania at the University of Dar es Salaam 
• Developed a deeper understanding for the important of cross cultural exchange 
and solidarity through building relationships with members of the community 
 
College of the Holy Cross: Department of Mathematics  
Worcester, MA| September 2011- May 2013| Student Advisory Committee  
• Distributed and reviewed student course evaluations  
• Involved in the hiring and promotion of new and existing professors  
 
College of the Holy Cross: Spring Break Immersion   
Lynchburgh, VA | March 2008 | L’Arche USA Volunteer  
• Spent a week living and working with L’Arche community members 
• Formed relationships with adults living with disabilities  
------------------------------------------------------------------------------------------------------------ 
PUBLICATIONS 
------------------------------------------------------------------------------------------------------------ 
• Legrand M, Vaidya V, De Berardinis B, Gaggin HK, Magrini L, Belcher A, 
Zancla B, Femia A, Simon M, Motiwala S, Sambhare R, Disomma S, Mebazaa 
A, and Januzzi JL.  Evidence of uncoupling between renal dysfunction and injury 
in cardiorenal syndrome: insights from the BIONICS study.  pLOS One, In Press. 
 
• Gaggin HK, Dang PV, Do LD, deFillippi CR, Christenson RH, Lewandrowski 
EL, Lewandrowski KB, Truong BQ, Pham VQ, Vu VG, Vu TV, Nguygen TB, 
Belcher AM, Femia, A, Kelley C, Januzzi J. Reference interval evaluation of 
high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam 
and the US: The North South East West Trial. Clinical Chemistry 
2014;60(5):758-64. 
	  69 
• Berardinis, B. D., Magrini, L., Gaggin, H. K., Belcker, A., Zancla, B., Femia, A., 
... Januzzi, J. L. (2013). A Prospective Blinded Study of Bioimpedance Vector 
Analysis and Biomarker Testing for the Prediction of Worsening Renal Function 
in Consecutive Patients with Acutely Decompensated Heart Failure: Primary 
Results of the Biomonitoring and Cardiorenal Syndrome in Heart Failure 
(BIONICS-HF) Trail. Journal of the American College of Cardiology, 61(10_S). 
doi:10.1016/S0735-1097(13)60639-7  
 
